Home>>Peptides>>Atrial natriuretic factor (1-28) (rat)

Atrial natriuretic factor (1-28) (rat)

Catalog No.GC11314

Atrial natriuretic factor (1-28) (rat) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.

Products are for research use only. Not for human use. We do not sell to patients.

Atrial natriuretic factor (1-28) (rat) Chemical Structure

Cas No.: 88898-17-3

Size Price Stock Qty
1mg
$246.00
Ship Within 7 Days

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Atrial Natriuretic Peptide (ANP) (1-28), rat is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.

Rat ANP (1-28) and rat BNP-45, which are the respective major circulating forms of ANP and BNP in rats, potently inhibited Ang II-stimulated endothelin-1 secretion in a concentration-dependent manner. Rat ANP (5-25) is less effective that Rat ANP(1-28) with respect to inhibiting immunoreactive (ir)-endothelin-1 secretion and increasing cellular cyclic GMP. Rat ANP (1-28) inhibits the secretion of ir-endothelin-1 in a concentration-dependent manner between 0.01 and 1 μM[1].

References:
[1]. Kohno M, et al. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int. 1992 Oct;42(4):860-6.

Reviews

Review for Atrial natriuretic factor (1-28) (rat)

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Atrial natriuretic factor (1-28) (rat)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.